Form PREC14A - Preliminary proxy statements, contested solicitations:
SEC Accession No. 0001999371-25-002912
Filing Date
2025-03-20
Accepted
2025-03-20 16:10:06
Documents
24

Document Format Files

Seq Description Document Type Size
1 PRELIMINARY PROXY STATEMENT opus-prec14a_032025.htm PREC14A 1121032
2 GRAPHIC opus-001.jpg GRAPHIC 6265
3 GRAPHIC opusprec14a001.jpg GRAPHIC 3537
4 GRAPHIC opusprec14a002.jpg GRAPHIC 2980
5 GRAPHIC opusprec14a003.jpg GRAPHIC 693
6 GRAPHIC opusprec14a004.jpg GRAPHIC 713
7 GRAPHIC opusprec14a005.jpg GRAPHIC 690
8 GRAPHIC opusprec14a006.jpg GRAPHIC 699
9 GRAPHIC opusprec14a007.jpg GRAPHIC 692
10 GRAPHIC opusprec14a009.jpg GRAPHIC 470
11 GRAPHIC opusprec14a010.jpg GRAPHIC 2419
12 GRAPHIC opusprec14a011.jpg GRAPHIC 4207
13 GRAPHIC opusprec14a012.jpg GRAPHIC 2789
14 GRAPHIC opusprec14a013.jpg GRAPHIC 3137
15 GRAPHIC opusprec14a014.jpg GRAPHIC 3349
16 GRAPHIC opusprec14a015.jpg GRAPHIC 2808
17 GRAPHIC opusprec14a016.jpg GRAPHIC 3222
18 GRAPHIC opusprec14a017.jpg GRAPHIC 3165
19 GRAPHIC opusprec14a018.jpg GRAPHIC 3416
20 GRAPHIC opusprec14a020.jpg GRAPHIC 59917
21 GRAPHIC proxycard001.jpg GRAPHIC 3640
22 GRAPHIC proxycard002.jpg GRAPHIC 648
23 GRAPHIC proxycard003.jpg GRAPHIC 536
24 GRAPHIC proxycard004.jpg GRAPHIC 4757
  Complete submission text file 0001999371-25-002912.txt   1284288
Mailing Address 8 DAVIS DRIVE SUITE 220 DURHAM NC 27709
Business Address 8 DAVIS DRIVE SUITE 220 DURHAM NC 27709 248-681-9815
Opus Genetics, Inc. (Filed by) CIK: 0001228627 (see all company filings)

EIN.: 113516358 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PREC14A
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 8 DAVIS DRIVE SUITE 220 DURHAM NC 27709
Business Address 8 DAVIS DRIVE SUITE 220 DURHAM NC 27709 248-681-9815
Opus Genetics, Inc. (Subject) CIK: 0001228627 (see all company filings)

EIN.: 113516358 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PREC14A | Act: 34 | File No.: 001-34079 | Film No.: 25756520
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)